Daiichi Sankyo And Merck Announce Collaboration To Develop And Commercialize Three DXd ADCs Globally, Excluding Japan
Portfolio Pulse from Benzinga Newsdesk
Merck and Daiichi Sankyo have announced a collaboration to develop and commercialize three DXd ADCs globally, excluding Japan. Merck will pay Daiichi Sankyo upfront payments totaling $4.5 billion and up to an additional $5.5 billion for each DXd ADC contingent upon the achievement of certain sales milestones. The total potential consideration across the three programs is up to $22 billion.
October 20, 2023 | 7:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Daiichi Sankyo's collaboration with Merck could lead to significant financial inflows, with potential payments up to $22 billion. This could positively impact Daiichi Sankyo's financial position and stock price.
The collaboration with Merck involves significant financial inflows for Daiichi Sankyo, which could boost its financial position and potentially its stock price. The total potential consideration across the three programs is up to $22 billion, which is a substantial amount.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Merck's collaboration with Daiichi Sankyo could lead to significant financial commitments, with potential payments up to $22 billion. This could impact Merck's financial position and stock price.
The collaboration with Daiichi Sankyo involves significant financial commitments from Merck, which could impact its financial position and potentially its stock price. The total potential consideration across the three programs is up to $22 billion, which is a substantial amount.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100